Physician profile
Wayne Leblanc
NPI 1023585254
$2,878.48
in general payments reported to CMS, 2019-2025
23 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $449 · 2023: $524 · 2024: $913 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $885.99 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $490.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $308.01 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $199.03 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $174.30 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Scpharmaceuticals INC. | $113.74 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $87.24 | 2023-2025 | Rexulti |
| Si-Bone, INC. | $77.10 | 2021 | |
| Glaxosmithkline, LLC. | $74.26 | 2021-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $71.70 | 2024-2025 | |
| Exact Sciences Corporation | $51.49 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $49.69 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.08 | 2024 | |
| Dexcom, INC. | $35.23 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $34.49 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $32.01 | 2025 | Auvelity |
| Silk Road Medical, INC. | $30.07 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Insulet Corporation | $27.41 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $23.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.65 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.27 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $17.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.35 | 2024 | Synjardy, Jardiance, Tradjenta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.